Neumora Q2 Loss Narrows, Advances CNS Pipeline; Names Joshua Pinto CEO

Neumora Therapeutics (NMRA) reported Q2 2026 net loss of $43.1 million, narrowing from $52.7 million a year earlier. Cash and equivalents stood at $116.8 million, expected to fund operations into Q3 2027.